Boone Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Boone Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-151,815	Closed	-$21.5M	–	16
2025 Q4	$21.5M	Sell	151,815 -14,599	-9%	-$2.11M	6.76%	6
2025 Q3	$23.4M	Sell	166,414 -13,924	-8%	-$1.89M	7.66%	6
2025 Q2	$22.7M	Buy	+180,338	New	+$20.7M	9.72%	6

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boone Capital Management's NBIX Position: Q1 2026 in Review

Boone Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 151,815 shares — an estimated $21.5M sold.

Boone Capital Management first reported a position in NBIX in Q2 2025 and held it in 3 quarters. The position peaked at $23.4M in Q3 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Boone Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Boone Capital Management sold 151,815 Neurocrine Biosciences shares in Q1 2026, an estimated $21.5M.
Boone Capital Management first reported a position in Neurocrine Biosciences in Q2 2025 and held it in 3 quarters.
Boone Capital Management's Neurocrine Biosciences position peaked at $23.4M in Q3 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Boone Capital Management's 13F filing for Q1 2026, filed 15 May 2026.